| Literature DB >> 29423386 |
Fatemeh Rahrovani1, Mohammad Hassan Javanbakht1, Ehsan Ghaedi1,2, Hamed Mohammadi3,4, Amir-Hooshang Ehsani5, Ali Esrafili6, Mahmoud Djalali1.
Abstract
Studies have reported different changes in the fatty acid composition of red blood cell (RBC) total lipids in patients with various types of cancer. It has been indicated that n-3/n-6 ratio plays a key role in the general consequence of skin photocarcinogenesis. However, to our knowledge there was no study examining the unsaturated fatty acid profile in basal cell carcinoma (BCC) patients. So, we explore the fatty acid composition of RBCs in newly diagnosed BCC patients in a hospital-based case-control study. This study has been conducted on new case BCC patients in Razi Hospital, Tehran, Iran. Fatty acid concentration in erythrocyte membranes defined as relative values after extraction, purification and preparation, by gas chromatography.Analysis revealed that heptadecenoic acid (p = 0.010) and oleic acid (p < 0.001) was significantly higher in BCC patients in comparison with control group. Among polyunsaturated fatty acids (PUFAs), linoleic acid (LA), and arachidonic acid (AA) were significantly higher in BCC patients (p < 0.001). It has been indicated that n-3 was significantly lower (p = 0.040) and n-6 was significantly higher (p = 0.002) in BCC patients. In addition, total PUFA (p < 0.001) and n-6 PUFAs/n-3 PUFAs (p = 0.002) were significantly higher in BCC patients compared to the control group. Here we indicated that new case BCC patient had significantly higher n-6 PUFA and lower n-3 along with other differences in unsaturated fatty acid in comparison with healthy subjects. Our study provides evidence that lipids are important in BCC development.Entities:
Keywords: Basal cell carcinoma; Erythrocyte membrane; Monounsaturated fatty acid; Polyunsaturated fatty acids
Year: 2018 PMID: 29423386 PMCID: PMC5796920 DOI: 10.7762/cnr.2018.7.1.21
Source DB: PubMed Journal: Clin Nutr Res ISSN: 2287-3732
Demographic characteristics and medical history of healthy and BCC group
| Demographic characteristics | BCC | Control | p value* | |
|---|---|---|---|---|
| Sex | Male | 28 (70) | 21 (52.5) | 0.18† |
| Female | 12 (30) | 19 (47.5) | ||
| Age, yr | 57.76 ± 1.56 | 54.05 ± 1.16 | 0.06* | |
| Weight, kg | 72.39 ± 1.94 | 72.48 ± 2.46 | 0.98* | |
| Height, cm | 167.76 ± 1.59 | 166.30 ± 1.36 | 0.49* | |
| BMI, kg/m2 | 26. 02 ± 0.74 | 25.74 ± 0.67 | 0.78* | |
Values are presented as number of patients (%) or mean ± SEMs.
BCC, basal cell carcinoma; BMI, body mass index; SEM, standard error of mean.
*p value is reported based on independent Samples t-test; †p value is reported based on χ2 test.
Energy, macronutrients, and micronutrients intakes of BCC subjects and control group
| Variables | BCC (n=40) | Control (n=40) | p value* |
|---|---|---|---|
| Total energy, kcal | 2,537.65 ± 146.68 | 2,246.55 ± 234.98 | 0.27 |
| Total carbohydrate, g | 327.32 ± 23.78 | 320.00 ± 27.55 | 0.86 |
| Total protein, g | 68.85 ± 3.33 | 68.90 ± 4.99 | 0.99 |
| Total fat, g | 80.82 ± 6.02 | 85.49 ± 8.09 | 0.65 |
| SFAs, g | 20.22 ± 1.91 | 17.57 ± 1.55 | 0.36 |
| MUFAs, g | 29.69 ± 2.08 | 29.63 ± 2.84 | 0.62 |
| PUFAs, g | 30.41 ± 3.36 | 36.06 ± 6.39 | 0.39 |
| Cholesterol, mg | 115.37 ± 39.94 | 120.42 ± 11.65 | 0.74 |
| Oleic fat, g | 19.56 ± 2.06 | 23.24 ± 2.20 | 0.26 |
| Linolenic fat, g | 2.47 ± 1.33 | 1.33 ± 0.39 | 0.54 |
| Linoleic, g | 28.47 ± 3.19 | 34.27 ± 21.18 | 0.37 |
| DHA, g | 0.02 ± 0.01 | 0.00 ± 0.00 | 0.39 |
| EPA, g | 0.01 ± 0.00 | 0.00 ± 0.00 | 0.43 |
| Molybdenum, µg | 46.56 ± 13.60 | 41.49 ± 10.03 | 0.80 |
| Selenium, mg | 0.22 ± 0.15 | 0.04 ± 0.00 | 0.38 |
| Chromium, mg | 0.05 ± 0.00 | 0.03 ± 0.00 | 0.11 |
| Copper, mg | 1.40 ± 0.20 | 1.20 ± 0.15 | 0.49 |
| Zinc, mg | 8.38 ± 0.53 | 9.27 ± 0.81 | 0.34 |
| Alpha tocopherol, mg | 12.63 ± 1.60 | 14.36 ± 2.86 | 0.57 |
| Beta carotene, µg | 613.55 ± 186.05 | 538.35 ± 220.61 | 0.80 |
Values are presented as mean ± SEMs.
BCC, basal cell carcinoma; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; SEM, standard error of mean.
*p value is reported based on independent Samples t-test.
MUFAs and PUFAs of RBC membrane in BCC subjects and control group
| Variables | BCC | Control | p value* | |
|---|---|---|---|---|
| MUFAs, % | ||||
| Myristoleic acid C 14:1 | 0.01 ± 0.01 | 0.02 ± 0.01 | 0.22 | |
| C 15:1 | 0.10 ± 0.01 | 0.11 ± 0.01 | 0.50 | |
| Palmitoleic acid C 16:1 | 0.01 ± 0.01 | 0.05 ± 0.02 | 0.61 | |
| Heptadecenoic acid C 17:1 | 0.11 ± 0.02 | 0.18 ± 0.01 | 0.01* | |
| Elaidic acid C 18:1 trans | 0.01 ± 0.01 | 0.02 ± 0.01 | 0.25 | |
| Oleic acid C 18:1 cis | 0.06 ± 0.01 | 0.03 ± 0.01 | <0.001* | |
| Gondoic acid C 20:1 | 0.01± 0.01 | 0.01 ± 0.01 | 0.90 | |
| Heneicosenoic acid C 21:1 | 0.04 ± 0.02 | - | - | |
| Nervonic acid C 24:1 | 0.19 ± 0.11 | 0.70 ± 0.02 | 0.31 | |
| PUFAs, % | ||||
| C 18:2 trans | 0.04 ± 0.01 | 0.03 ± 0.01 | 0.21 | |
| LA C 18:2 cis | 0.06 ± 0.01 | 0.02 ± 0.01 | <0.001* | |
| γ-linolenic acid C 18:3(6,9,12) | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.36 | |
| α-linolenic acid C 18:3(9,12,15) | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.35 | |
| Eicosadienoic acid C 20:2 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.22 | |
| Dihomo-γ-linolenic acid C 20:3(8,11,14) | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.06 | |
| AA C 20:4 | 0.04 ± 0.01 | 0.01 ± 0.01 | <0.001* | |
| Docosadienoic acid C 22:2 | 0.02 ± 0.01 | 0.01 ± 0.01 | 0.17 | |
| Eicosatrienoic acid C 20:3(11,14,17) | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.06 | |
| EPA C 20:5 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.83 | |
| DHA C 22:6 | 0.07 ± 0.01 | 0.08 ± 0.01 | 0.68 | |
Values are presented as mean ± SEMs.
MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; RBC, red blood cell; BCC, basal cell carcinoma; LA, linoleic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; SEM, standard error of mean.
*pvalue is reported based on independent Samples t-testand less than 0.05 was considered statistically significant.
Fatty acid product to precursor ratio and practical ratios between fatty acids of RBC membrane in BCC subjects and control group
| Variables | BCC | Control | p value* |
|---|---|---|---|
| Total PUFAs | 0.24 ± 0.01 | 0.14 ± 0.01 | < 0.001 |
| n-3 HUFAs | 0.08 ± 0.01 | 0.09 ± 0.01 | 0.67 |
| n-3 fatty acids | 0.06 ± 0.01 | 0.11 ± 0.02 | 0.04* |
| n-6 fatty acids | 0.12 ± 0.01 | 0.07 ± 0.01 | 0.002* |
| n-3/n-6 fatty acids | 1.40 ± 0.51 | 7.90 ± 5.82 | 0.31 |
| n-6 PUFAs/n-3PUFAs | 2.51 ± 0.35 | 1.15 ± 0.19 | 0.002 |
| n-6 PUFAs/n-3HUFAs | 12.41 ± 9.99 | 4.58 ± 2.61 | 0.45 |
| AA/EPA 20:4n-6/20:5n-3 | 2.79 ± 1.31 | 0.68 ± 0.22 | 0.13 |
| AA/DHA 20:4n-6/22:6n-3 | 1.05 ± 0.32 | 1.26 ± 0.70 | 0.81 |
Values are presented as mean ± SEMs.
RBC, red blood cell; BCC, basal cell carcinoma; PUFA, polyunsaturated fatty acid; HUFA, highly unsaturated fatty acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; SEM, standard error of mean.
*p value is reported based on independent Samples t-test and less than 0.05 was considered statistically significant.